GUT:中国胃癌患者易感基因的全基因组关联及功能分析

2019-08-13 MedSci MedSci原创

研究人员确定了12个与中国人群中GC风险相关的基因,并解释了5p13.1-PRKAA1和10q23.33-noc3l在胃癌发生机制中的作用

目的遗传位点与癌(GC)的风险相关的潜在机制尚不清楚,近日研究人员考察了新易感基因与GC发育的相关机制。

研究人员对四项全基因组关联研究(GWASs)进行了Meta分析,包括3771例病例和5426例对照者。在靶向测序和功能注释后,进行了体外和体内实验,以确定基因变异和候选基因的功能。此外,我们从其他5项研究中选出了7035例病例和8323例对照者,对33种变异体的GC相关性进行了考察。

GWASs的Meta分析发现,在p<5×10-8时,1q22、5p13.1和10q23.33位点突变与癌风险相关,在p<0.05时验证了7个已知位点。对于5p13.1位点,rs59133000[C]等位基因增强NF-κB1(核因子κB亚基1)与PRKAA1启动子的结合亲和力,导致启动子活性降低,表达降低。PRKAA1基因敲除对胃癌细胞增殖和裸鼠移植瘤生长均有促进作用。对于10q23.33位点,rs3781266[C]和rs 3740365[T]风险等位基因在完全连锁不平衡状态下,分别破坏和产生了POU2F1和PAX 3的结合基序,从而增强了NOC3L的活性和表达,而NOC3L的敲除抑制了GC细胞的生长。另外发现了3q11.2(OR=1.21)和4q28.1(OR=1.14)两个胃癌风险相关位点。

研究人员确定了12个与中国人群中GC风险相关的基因,并解释了5p13.1-PRKAA1和10q23.33-noc3l在胃癌发生机制中的作用。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1769677, encodeId=1e2f1e6967727, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83234, encryptionId=900b8323461, topicName=胃癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=377c38086944, createdName=huhuaidong400, createdTime=Wed Dec 04 03:14:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809973, encodeId=19af18099e36d, content=<a href='/topic/show?id=2b9d8426121' target=_blank style='color:#2F92EE;'>#能分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84261, encryptionId=2b9d8426121, topicName=能分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Feb 13 09:14:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394457, encodeId=6364139445e37, content=<a href='/topic/show?id=7deb59659b9' target=_blank style='color:#2F92EE;'>#易感基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59659, encryptionId=7deb59659b9, topicName=易感基因)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/72D57F5B3E12B2BB53D6BD015D14DCD6/100, createdBy=a92e2500162, createdName=passed water, createdTime=Thu Aug 15 10:14:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546511, encodeId=dfa615465119a, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Thu Aug 15 10:14:00 CST 2019, time=2019-08-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1769677, encodeId=1e2f1e6967727, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83234, encryptionId=900b8323461, topicName=胃癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=377c38086944, createdName=huhuaidong400, createdTime=Wed Dec 04 03:14:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809973, encodeId=19af18099e36d, content=<a href='/topic/show?id=2b9d8426121' target=_blank style='color:#2F92EE;'>#能分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84261, encryptionId=2b9d8426121, topicName=能分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Feb 13 09:14:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394457, encodeId=6364139445e37, content=<a href='/topic/show?id=7deb59659b9' target=_blank style='color:#2F92EE;'>#易感基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59659, encryptionId=7deb59659b9, topicName=易感基因)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/72D57F5B3E12B2BB53D6BD015D14DCD6/100, createdBy=a92e2500162, createdName=passed water, createdTime=Thu Aug 15 10:14:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546511, encodeId=dfa615465119a, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Thu Aug 15 10:14:00 CST 2019, time=2019-08-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1769677, encodeId=1e2f1e6967727, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83234, encryptionId=900b8323461, topicName=胃癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=377c38086944, createdName=huhuaidong400, createdTime=Wed Dec 04 03:14:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809973, encodeId=19af18099e36d, content=<a href='/topic/show?id=2b9d8426121' target=_blank style='color:#2F92EE;'>#能分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84261, encryptionId=2b9d8426121, topicName=能分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Feb 13 09:14:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394457, encodeId=6364139445e37, content=<a href='/topic/show?id=7deb59659b9' target=_blank style='color:#2F92EE;'>#易感基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59659, encryptionId=7deb59659b9, topicName=易感基因)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/72D57F5B3E12B2BB53D6BD015D14DCD6/100, createdBy=a92e2500162, createdName=passed water, createdTime=Thu Aug 15 10:14:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546511, encodeId=dfa615465119a, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Thu Aug 15 10:14:00 CST 2019, time=2019-08-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1769677, encodeId=1e2f1e6967727, content=<a href='/topic/show?id=900b8323461' target=_blank style='color:#2F92EE;'>#胃癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83234, encryptionId=900b8323461, topicName=胃癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=377c38086944, createdName=huhuaidong400, createdTime=Wed Dec 04 03:14:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809973, encodeId=19af18099e36d, content=<a href='/topic/show?id=2b9d8426121' target=_blank style='color:#2F92EE;'>#能分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84261, encryptionId=2b9d8426121, topicName=能分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Feb 13 09:14:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394457, encodeId=6364139445e37, content=<a href='/topic/show?id=7deb59659b9' target=_blank style='color:#2F92EE;'>#易感基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59659, encryptionId=7deb59659b9, topicName=易感基因)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/72D57F5B3E12B2BB53D6BD015D14DCD6/100, createdBy=a92e2500162, createdName=passed water, createdTime=Thu Aug 15 10:14:00 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546511, encodeId=dfa615465119a, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Thu Aug 15 10:14:00 CST 2019, time=2019-08-15, status=1, ipAttribution=)]

相关资讯

腹腔镜胃癌根治术的优势有哪些?

在我国胃癌的发病率很高,然而胃癌的早期诊断率比较低,给胃癌的治疗带来不便。那么您了解胃癌吗? 胃癌的诱发因素众多,如地域环境、饮食生活方式(长期食用盐腌、熏烤食品)、幽门螺杆菌感染、慢性疾患及遗传等因素。胃癌按照肿瘤侵犯程度的不同可分为早期胃癌和进展期胃癌。

中国幽门螺杆菌根除与胃癌防控的专家共识意见(2019年,上海)

我国是胃癌和H·pylori感染的双重高发国家,H·pylori感染和胃癌的发生关系密切,二者的危害相互叠加,重视H·pylori感染的防治是预防胃癌的必由之路。本共识基于循证医学依据和Delphi方法,在H·pylori感染与胃癌的关系、H·pylori根除与胃癌预防、H·pylori筛查与根除策略3个领域达成初步共识。本共识进一步理清了H·pylori与胃癌的关系,以及如何依据二者关系制定今后

Diabetes Care:糖尿病患者根除幽门螺杆菌后胃癌风险增加

由此可见,2型糖尿病与HP根除患者的GC风险增加有关,特别是那些DM控制不佳的患者。

Oncologie宣布与Merck进行临床试验合作,评估Bavituximab与PD-1单抗KEYTRUDA联合治疗晚期胃癌或胃食管癌

Oncologie,一家开发针对肿瘤微环境创新肿瘤疗法的临床阶段生物制药公司,宣布已与默克公司达成临床合作协议,评估Oncologie的研究药物Bavituximab(一种阻断磷脂酰丝氨酸(PS)活性的抗体)和Merck的抗PD-1疗法KEYTRUDA(pembrolizumab)治疗晚期胃癌或胃食管癌潜力。

J Gastroenterol:胃癌“隐身面具细胞” 来源揭示——来自胃癌自身

先前研究认为幽门螺杆菌(H.pylori)是导致胃癌的主要原因。根除幽门螺杆菌能够抑制癌症的发生。但近来发现,部分患者在根除幽门螺杆菌后发仍有可能发生胃癌,发病率(每年0.24%)低于未根除者。

沈琳教授解读:PD-1抑制剂临“胃”不惧,突破三线治疗困局

近日,北京消化肿瘤国际高峰论坛暨中国胃肠肿瘤临床研究协作组年会(CGOG)在北京召开。会议期间,北京大学肿瘤医院副院长沈琳教授接受了肿瘤资讯的采访,解答了目前业界最为关心的胃癌免疫治疗相关问题,并对未来胃癌免疫治疗的发展提出了思考与启示。亮点一览中国胃癌发病率高,早诊率低,有效治疗手段匮乏,免疫治疗是目前最有前景的治疗手段。ATTRACTION-2研究开辟了胃癌免疫治疗之先河;单药之后,免疫联